Functional Evaluation of Irreversible Electroporation for a Pancreatic Nonfunctioning Neuroendocrine Tumor Using 68Ga-DOTATOC PET/CT.

Fiche publication

Date publication

novembre 2025

Journal

Clinical nuclear medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GARNON Julien , Pr IMPERIALE Alessio , Dr BALTZINGER Philippe

Tous les auteurs :
Ait Talhiq H, Baltzinger P, Achille M, Addeo P, Garnon J, Imperiale A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41359674

Résumé

Percutaneous irreversible electroporation (IRE) is a nonthermal ablation technique increasingly used for pancreatic malignancies, though rarely reported in pancreatic neuroendocrine tumors (pNETs). We present the case of a 75-year-old man with a well-differentiated grade-1 nonfunctioning pNET treated by percutaneous IRE after refusing surgery. Posttreatment somatostatin receptors PET/CT showed a marked reduction in 68Ga-DOTATOC uptake at 1 month, followed by stable residual activity at 1 year, despite complete devascularization on contrast-enhanced CT. This case illustrates the potential of IRE to achieve durable tumor control and highlights the added value of PET/CT in assessing functional response beyond morphology.